GLPwatch
Papers (12034)
Page 87 of 201, ranked by citation count.
- Distinct effects of dipeptidyl peptidase-4 inhibitor and glucagon-like peptide-1 receptor agonist on islet morphology and function.
- Evaluation of the efficacy of low-dose liraglutide in weight control among Taiwanese non-diabetes patients.
- Improved glycemic and weight control with Dulaglutide addition in SGLT2 inhibitor treated obese type 2 diabetic patients at high cardiovascular risk in a real-world setting. The AWARE-2 study.
- Semaglutide versus other GLP-1 receptor agonists in patients with MASLD.
- Management of obesity with semaglutide or metformin in patients with antipsychotic-induced weight gain (MOSA): a non-randomised open-label pilot study.
- Patient initiation and maintenance of GLP-1 RAs for treatment of obesity: a narrative review and practical considerations for primary care providers.
- High-dose liraglutide improves metabolic syndrome in poor responders to bariatric surgery.
- Medicinal Plants Qua Glucagon-Like Peptide-1 Secretagogue via Intestinal Nutrient Sensors.
- Semaglutide restores astrocyte-vascular interactions and blood-brain barrier integrity in a model of diet-induced metabolic syndrome.
- Glycaemic and non-glycaemic efficacy of once-weekly GLP-1 receptor agonists in people with type 2 diabetes.
- Cardioprotective effects of liraglutide pretreatment on isoprenaline-induced myocardial injury in rats.
- The transcription factor E2F1 controls the GLP-1 receptor pathway in pancreatic β cells.
- Population pharmacodynamic modeling of exenatide after 2-week treatment in STZ/NA diabetic rats.
- A Plethora of GLP-1 Agonists: Decisions About What to Use and When.
- GLP-1 receptor agonist liraglutide exerts central action to induce β-cell proliferation through medulla to vagal pathway in mice.
- Liraglutide in the treatment of type 2 diabetes mellitus: clinical utility and patient perspectives.
- The Effectiveness and Safety of Exenatide Versus Metformin in Patients with Polycystic Ovary Syndrome: A Meta-Analysis of Randomized Controlled Trials.
- Tirzepatide and potential use for metabolically healthy obesity.
- Differential Effects of Type 2 Diabetes Treatment Regimens on Diabetes Distress and Depressive Symptoms in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).
- GLP-1 receptor agonists in type 1 diabetes: a proof-of-concept approach.
- Semaglutide use is associated with higher rates of pseudarthrosis and dysphagia in patients undergoing posterior cervical fusion.
- Once-Weekly Exenatide and Cardiovascular Outcomes in Type 2 Diabetes.
- Principal components analysis on genes related to inflammasome complex and microglial activation in the hypothalamus of obese mice treated with semaglutide (GLP-1 analog).
- Insulin and GLP-1 analog combinations in type 2 diabetes mellitus: a critical review.
- An oral GLP-1 and GIP dual receptor agonist improves metabolic disorders in high fat-fed mice.
- GLP-1RA in the Real World: 1-year Compliance and Outcomes of Semaglutide use in Patients With or Without Previous History of Bariatric Surgery.
- Efficacy of Exenatide Plus Pioglitazone Vs Basal/Bolus Insulin in T2DM Patients With Very High HbA1c.
- Factors associated with successful weight loss after liraglutide treatment for obesity.
- The role of gastric function in control of food intake (and body weight) in relation to obesity, as well as pharmacological and surgical interventions.
- Effects of Liraglutide on Worsening Renal Function Among Patients With Heart Failure With Reduced Ejection Fraction: Insights From the FIGHT Trial.
- Development of an <sup>111</sup>In-Labeled Glucagon-Like Peptide-1 Receptor-Targeting Exendin-4 Derivative that Exhibits Reduced Renal Uptake.
- 10-fold liraglutide overdose over 7 months resulted only in minor side-effects.
- Drug Delivery Strategies for Enhancing the Therapeutic Efficacy of Toxin-Derived Anti-Diabetic Peptides.
- Long-acting PYY<sub>3</sub> <sub>-36</sub> analogue with semaglutide for obesity: from preclinical assessment through randomized clinical studies.
- Administration of the GLP-1 receptor agonist exenatide in rats improves functional recovery after spinal cord injury by reducing endoplasmic reticulum stress.
- Role of GLP-1 Receptor Agonists in Pediatric Obesity: Benefits, Risks, and Approaches to Patient Selection.
- The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia.
- Dulaglutide accelerates diabetic wound healing by suppressing Nrf2-dependent ferroptosis in diabetic mice.
- Exenatide once weekly for smoking cessation: study protocol for a randomized clinical trial.
- GLP-1 agonist liraglutide improves ouabain-induced mania and depressive state <i>via</i> GSK-3β pathway.
- Metformin, sitagliptin, and liraglutide modulate serum retinol-binding protein-4 level and adipocytokine production in type 2 diabetes mellitus rat model.
- Alternate-day fat diet and exenatide modulate the brain leptin JAK2/STAT3/SOCS3 pathway in a fat diet-induced obesity and insulin resistance mouse model.
- Effect of Liraglutide in Different Abdominal Fat Layers Measured by Ultrasound: The Importance of Perirenal Fat Reduction.
- Using Exenatide Twice Daily or Insulin in Clinical Practice: Results from CHOICE.
- Bullous pemphigoid triggered by dulaglutide: a case report and a review of the literature.
- PDGF Facilitates Direct Lineage Reprogramming of Hepatocytes to Functional β-Like Cells Induced by Pdx1 and Ngn3.
- Liraglutide Pretreatment Does Not Improve Acute Doxorubicin-Induced Cardiotoxicity in Rats.
- Tirzepatide: Clinical review of the "twincretin" injectable.
- Emerging role of GLP-1 agonists in cardio-metabolic therapy - Focus on Semaglutide.
- Evidence-Based Cardiovascular Risk Management in Diabetes.
- Cardiovascular disease leads to a new algorithm for diabetes treatment.
- Nasal absorption enhancement of protein drugs independent to their chemical properties in the presence of hyaluronic acid modified with tetraglycine-L-octaarginine.
- Three years of liraglutide treatment offers continuously optimal glycemic control in a pediatric patient with maturity-onset diabetes of the young type 3.
- A Multidisciplinary Perspective on Semaglutide Treatment and Medical Nutrition Therapy in Obesity Management.
- Liraglutide preconditioning attenuates myocardial ischemia/ reperfusion injury via homer1 activation.
- Effects of HbA1c and weight reduction on blood pressure in patients with type 2 diabetes mellitus treated with exenatide*.
- Long-Term Cost-Effectiveness of Subcutaneous Once-Weekly Semaglutide Versus Polyethylene Glycol Loxenatide for Treatment of Type 2 Diabetes Mellitus in China.
- Exenatide: a new promising antidiabetic agent.
- Liraglutide Alleviates Diabetic Atherosclerosis through Regulating Calcification of Vascular Smooth Muscle Cells.
- Titration and discontinuation of semaglutide for weight management in commercially insured US adults.